Expression conditions and characterization of a novelly constructed lipoprotein intended as a vaccine to prevent human Haemophilus influenzae infections.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
08 2023
Historique:
received: 23 02 2023
revised: 16 06 2023
accepted: 01 07 2023
medline: 31 8 2023
pubmed: 13 7 2023
entrez: 12 7 2023
Statut: ppublish

Résumé

Bacterial lipoproteins are structurally divided into two groups, based on their lipid moieties: diacylated (present in Gram-positive bacteria) and triacylated (present in some Gram-positive and most Gram-negative bacteria). Diacylated and triacylated lipid moieties differ by a single amide-linked fatty acid chain. Lipoproteins induce host innate immune responses by the mammalian Toll-like receptor 2 (TLR2). In this study, we added a lipid moiety to recombinant OMP26, a native nonlipidated (NL) membrane protein of Haemophilus influenzae, and characterized it extensively under different expression conditions using flow cytometry, LC/MS, and MALDI-TOF. We also investigated the ability of NL and lipidated (L) OMP26 to induce in vitro stimulation of HEK Blue-hTLR2-TR1 and hTLR-TLR6 cells. Our L-OMP26 was predominantly expressed in diacylated form, so we employed an additional gene copy of apolipoprotein N-acetyltransferase enzyme (Lnt)-rich Escherichia coli strain that further acylates the diacyl lipoproteins to enhance the production of triacylated L-OMP26. The diacyl and triacyl versions of L-OMP26, intended as a vaccine for use in humans, were characterized and evaluated as protein vaccine components in a mouse model. We found that the diacyl and triacyl L-OMP26 protein formulations differed markedly in their immune-stimulatory activity, with diacylated L-OMP26 stimulating higher adaptive immune responses compared with triacylated L-OMP26 and both stimulating higher adaptive immune response compared to NL-OMP26. We also constructed and characterized an L-OMP26φNL-P6 fusion protein, where NL-P6 protein (a commonly studied H. influenzae vaccine candidate) was recombinantly fused to L-OMP26. We observed a similar pattern of lipidation (predominantly diacylated) in the L-OMP26φNL-P6 fusion protein.

Identifiants

pubmed: 37437888
pii: S0021-9258(23)02059-8
doi: 10.1016/j.jbc.2023.105031
pmc: PMC10407732
pii:
doi:

Substances chimiques

Bacterial Outer Membrane Proteins 0
Lipoproteins 0
Haemophilus Vaccines 0
Recombinant Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

105031

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI153936
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Ravinder Kaur (R)

Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. Electronic address: Ravinder.kaur@rochesterregional.org.

Jill Mangiafesto (J)

Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.

Karin Pryharski (K)

Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.

Sailee Rasam (S)

Department of Biochemistry, State University of New York at Buffalo, New York, USA.

Robert Zagursky (R)

Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA.

Michael Pichichero (M)

Center for Infectious Diseases and Immunology, Rochester General Hospital Research Institute, Rochester, New York, USA. Electronic address: Michael.pichichero@rochesterregional.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH